Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol)
- PMID: 9067319
Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol)
Abstract
The efficiency of drug accumulation in tumors was measured after intravenous administration of doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol liposomes prepared in the presence or absence of 5 mol % polyethylene glycol-modified phosphatidylethanolamine (PEG-PE). These liposomal formulations of doxorubicin were administered at the maximum tolerated dose in female BDF-1 mice bearing subcutaneously established Lewis Lung carcinoma. The parameters used to determine tumor targeting efficiency (T(e)) included area under the doxorubicin plasma (AUC(P)) and tumor (AUC(T)) concentration-time curves. Extended time-course studies evaluating lipid and drug levels in plasma and tumors during 7 days after administration indicated that the T(e) (AUC(T)/AUC(P)) was greater for liposomes that did not contain PEG-PE. The AUC(P) after administration of free doxorubicin, doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol liposomes and doxorubicin encapsulated in distearoyl phosphatidylcholine/cholesterol/PEG-PE-stabilized liposomes were 0.087 micromol x ml(-1) x h, 50 micromol x ml(-1) x h and 78 micromol x ml(-1) x h, respectively. Maximum drug levels achieved in the tumors were similar for both liposomal doxorubicin formulations, 140 microg (250 nmol)/g tumor; however, this level was achieved faster when the liposomes did not contain PEG-PE. Maximum levels measured after administration of free drug were less than 5 microg/g tumor, and these were achieved within 15 min. The results suggest that some of the benefits associated with the use of PEG-modified liposomes, such as increased blood levels and enhanced circulation lifetime, may be of little advantage in terms of maximizing liposomal drug accumulation in sites of tumor growth.
Similar articles
-
Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?Clin Cancer Res. 1999 Nov;5(11):3645-52. Clin Cancer Res. 1999. PMID: 10589782
-
Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?J Control Release. 2007 Apr 2;118(2):204-15. doi: 10.1016/j.jconrel.2006.12.002. Epub 2006 Dec 8. J Control Release. 2007. PMID: 17239468
-
Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes.Cancer Chemother Pharmacol. 1997;40(4):309-17. doi: 10.1007/s002800050662. Cancer Chemother Pharmacol. 1997. PMID: 9225948
-
[PEG-liposome in DDS and clinical studies].Nihon Rinsho. 1998 Mar;56(3):632-7. Nihon Rinsho. 1998. PMID: 9549348 Review. Japanese.
-
Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours.Drugs. 1997;54 Suppl 4:15-21. doi: 10.2165/00003495-199700544-00005. Drugs. 1997. PMID: 9361957 Review.
Cited by
-
Nonadditive Effects of Repetitive Administration of Lipoplexes in Immunocompetent Mice.J Pharm Sci. 2017 Mar;106(3):872-881. doi: 10.1016/j.xphs.2016.11.013. Epub 2016 Nov 22. J Pharm Sci. 2017. PMID: 27887890 Free PMC article.
-
Gold cluster encapsulated liposomes: theranostic agent with stimulus triggered release capability.Med Oncol. 2023 Mar 24;40(5):126. doi: 10.1007/s12032-023-01991-1. Med Oncol. 2023. PMID: 36961614
-
PEGylated versus Non-PEGylated pH-Sensitive Liposomes: New Insights from a Comparative Antitumor Activity Study.Pharmaceutics. 2022 Jan 24;14(2):272. doi: 10.3390/pharmaceutics14020272. Pharmaceutics. 2022. PMID: 35214005 Free PMC article.
-
Pegylated liposomal doxorubicin in ovarian cancer.Ther Clin Risk Manag. 2009 Jun;5(3):639-50. doi: 10.2147/tcrm.s5148. Epub 2009 Aug 20. Ther Clin Risk Manag. 2009. PMID: 19707541 Free PMC article.
-
Anticancer Effect of Metformin in Herceptin-Conjugated Liposome for Breast Cancer.Pharmaceutics. 2019 Dec 20;12(1):11. doi: 10.3390/pharmaceutics12010011. Pharmaceutics. 2019. PMID: 31877620 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources